Director, Global Pharmacovigilance (Safety) and Risk Management
Elan is a neuroscience-focused biotechnology company headquartered in Dublin, Ireland. It was incorporated as a private limited company in December 1969 and became a public limited company in January 1984. Elan's work includes research, development, and commercial activities for neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease and autoimmune diseases, including multiple sclerosis.